Carcinoma, Ovarian
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| Registry Platform Ovarian and Endometrial Cancer (NCT05129969) | iOMEDICO AG | 2021-11-25 |
Track Carcinoma, Ovarian automatically
Every clearance here is in the API, with alerts when new ones post.